308 related articles for article (PubMed ID: 30232145)
21. Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type.
Conlon N; Silva A; Guerra E; Jelinic P; Schlappe BA; Olvera N; Mueller JJ; Tornos C; Jungbluth AA; Young RH; Oliva E; Levine D; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):395-403. PubMed ID: 26645725
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R
Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886
[TBL] [Abstract][Full Text] [Related]
23. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
[TBL] [Abstract][Full Text] [Related]
24. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
[TBL] [Abstract][Full Text] [Related]
25. Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade.
Jelinic P; Ricca J; Van Oudenhove E; Olvera N; Merghoub T; Levine DA; Zamarin D
J Natl Cancer Inst; 2018 Jul; 110(7):787-790. PubMed ID: 29365144
[TBL] [Abstract][Full Text] [Related]
26. Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
Connor YD; Miao D; Lin DI; Hayne C; Howitt BE; Dalrymple JL; DeLeonardis KR; Hacker MR; Esselen KM; Shea M
Gynecol Oncol; 2020 Apr; 157(1):106-114. PubMed ID: 31954538
[TBL] [Abstract][Full Text] [Related]
27. c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.
Otte A; Rauprich F; von der Ohe J; Yang Y; Kommoss F; Feuerhake F; Hillemanns P; Hass R
Oncotarget; 2015 Oct; 6(31):31640-58. PubMed ID: 26436697
[TBL] [Abstract][Full Text] [Related]
28. Small Cell Carcinoma of Ovary, Hypercalcemic Type: A Rare Case Report.
Coşkun Ç; Kurucu N; Usubutun A; Soyer T; Ozcan HN; Çelik Ertaş NB; Kutluk T
J Pediatr Adolesc Gynecol; 2023 Apr; 36(2):112-115. PubMed ID: 36243275
[TBL] [Abstract][Full Text] [Related]
29. Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type.
Ji JX; Cochrane DR; Tessier-Cloutier B; Chen SY; Ho G; Pathak KV; Alcazar IN; Farnell D; Leung S; Cheng A; Chow C; Colborne S; Negri GL; Kommoss F; Karnezis A; Morin GB; McAlpine JN; Gilks CB; Weissman BE; Trent JM; Hoang L; Pirrotte P; Wang Y; Huntsman DG
Clin Cancer Res; 2020 Aug; 26(16):4402-4413. PubMed ID: 32409304
[TBL] [Abstract][Full Text] [Related]
30. Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
Gatla HR; Zou Y; Uddin MM; Singha B; Bu P; Vancura A; Vancurova I
J Biol Chem; 2017 Mar; 292(12):5043-5054. PubMed ID: 28167529
[TBL] [Abstract][Full Text] [Related]
31. The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases.
Witkowski L; Donini N; Byler-Dann R; Knost JA; Albrecht S; Berchuck A; McCluggage WG; Hasselblatt M; Foulkes WD
Fam Cancer; 2017 Jul; 16(3):395-399. PubMed ID: 27866340
[TBL] [Abstract][Full Text] [Related]
32. Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines.
Tischkowitz M; Huang S; Banerjee S; Hague J; Hendricks WPD; Huntsman DG; Lang JD; Orlando KA; Oza AM; Pautier P; Ray-Coquard I; Trent JM; Witcher M; Witkowski L; McCluggage WG; Levine DA; Foulkes WD; Weissman BE
Clin Cancer Res; 2020 Aug; 26(15):3908-3917. PubMed ID: 32156746
[TBL] [Abstract][Full Text] [Related]
33. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4.
Ramos P; Karnezis AN; Craig DW; Sekulic A; Russell ML; Hendricks WP; Corneveaux JJ; Barrett MT; Shumansky K; Yang Y; Shah SP; Prentice LM; Marra MA; Kiefer J; Zismann VL; McEachron TA; Salhia B; Prat J; D'Angelo E; Clarke BA; Pressey JG; Farley JH; Anthony SP; Roden RB; Cunliffe HE; Huntsman DG; Trent JM
Nat Genet; 2014 May; 46(5):427-9. PubMed ID: 24658001
[TBL] [Abstract][Full Text] [Related]
34. Identification of Driver Mutations in Rare Cancers: The Role of SMARCA4 in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT).
Lang JD; Hendricks WPD
Methods Mol Biol; 2018; 1706():367-379. PubMed ID: 29423809
[TBL] [Abstract][Full Text] [Related]
35. A Population-Based Study of Patients With Small Cell Carcinoma of the Ovary, Hypercalcemic Type, Encompassing a 30-Year Period.
Blatnik A; Dragoš VŠ; Blatnik O; Stegel V; Klančar G; Novaković S; Drev P; Žagar T; Merlo S; Škof E; Bojadžiski MP; Strojnik K; Krajc M
Arch Pathol Lab Med; 2024 Mar; 148(3):299-309. PubMed ID: 37270804
[TBL] [Abstract][Full Text] [Related]
36. The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.
Witkowski L; Goudie C; Ramos P; Boshari T; Brunet JS; Karnezis AN; Longy M; Knost JA; Saloustros E; McCluggage WG; Stewart CJR; Hendricks WPD; Cunliffe H; Huntsman DG; Pautier P; Levine DA; Trent JM; Berchuck A; Hasselblatt M; Foulkes WD
Gynecol Oncol; 2016 Jun; 141(3):454-460. PubMed ID: 26975901
[TBL] [Abstract][Full Text] [Related]
37. Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics.
Gamwell LF; Gambaro K; Merziotis M; Crane C; Arcand SL; Bourada V; Davis C; Squire JA; Huntsman DG; Tonin PN; Vanderhyden BC
Orphanet J Rare Dis; 2013 Feb; 8():33. PubMed ID: 23433318
[TBL] [Abstract][Full Text] [Related]
38. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
Jelinic P; Mueller JJ; Olvera N; Dao F; Scott SN; Shah R; Gao J; Schultz N; Gonen M; Soslow RA; Berger MF; Levine DA
Nat Genet; 2014 May; 46(5):424-6. PubMed ID: 24658004
[TBL] [Abstract][Full Text] [Related]
39. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
Fukumoto T; Park PH; Wu S; Fatkhutdinov N; Karakashev S; Nacarelli T; Kossenkov AV; Speicher DW; Jean S; Zhang L; Wang TL; Shih IM; Conejo-Garcia JR; Bitler BG; Zhang R
Cell Rep; 2018 Mar; 22(13):3393-3400. PubMed ID: 29590609
[TBL] [Abstract][Full Text] [Related]
40. Small Cell Carcinoma of Ovary, Hypercalcemic Type: Cytologic, Histopathologic, and Immunohistochemical Landscapes of a Rare Case.
Aggarwal D; Gupta P; Chhabra P; Peters NJ; Bansal D; Srinivasan R; Kakkar N
J Pediatr Adolesc Gynecol; 2021 Feb; 34(1):98-102. PubMed ID: 32750414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]